Alkermes vs Kiniksa Pharmaceuticals International
Alkermes (ALKS), health care, and Kiniksa Pharmaceuticals International (KNSA), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Alkermes is worth $7.6B on the stock market and Kiniksa Pharmaceuticals International $7.5B: Alkermes is valued at 2% more. Alkermes's operating margin in its latest fiscal year was 17.2% and Kiniksa Pharmaceuticals International's 11.4%. Over the past year Alkermes's share price has moved +59.0% and Kiniksa Pharmaceuticals International's +128%.
Key facts
- Alkermes market value
- $7.6B
- Kiniksa Pharmaceuticals International market value
- $7.5B
- Kiniksa Pharmaceuticals International P/E
- 72.1
- Alkermes revenue
- $1.5BFY to 2025-12-31
- Kiniksa Pharmaceuticals International revenue
- $677.6MFY to 2025-12-31
- Superinvestors holding both
- 1
Market values as of .
| Measure | Alkermes | Kiniksa Pharmaceuticals International |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size | ||
| Market cap | $7.6Bhigher | $7.5Blower |
| Revenue | $1.5Bhigher | $677.6Mlower |
| Earnings | $241.7Mhigher | $59Mlower |
| Employees | 2,050higher | 366lower |
| Total assets | $2.5Bhigher | $763.6Mlower |
| Valuation | ||
| P/E | — | 72.1 |
| P/S | 5.2lower | 11.0higher |
| P/B | — | — |
| Dividend yield | — | — |
| Profitability | ||
| Operating margin | 17.2%higher | 11.4%lower |
| Balance sheet | ||
| Net assets | $1.8Bhigher | $567.6Mlower |
| Total liabilities | $667.7Mhigher | $196Mlower |
| Total debt | — | — |
| Cash on hand | $388.6Mhigher | $165.6Mlower |
| Price change | ||
| Today | -2.32%lower | +0.93%higher |
| 1 year | +59.0%lower | +128%higher |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (1)
- Julian and Felix Baker2.6% / 0.9%
Alkermes only (3)
Kiniksa Pharmaceuticals International only (0)
None of the tracked investors.
Percentages are each holding's share of that investor's reported portfolio (under "Both": Alkermes / Kiniksa Pharmaceuticals International). Who owns ALKS · Who owns KNSA
More on Alkermes
More on Kiniksa Pharmaceuticals International
- Kiniksa Pharmaceuticals International (KNSA) stock page
- Kiniksa Pharmaceuticals International market cap
- Kiniksa Pharmaceuticals International revenue
- Kiniksa Pharmaceuticals International P/E ratio
- Kiniksa Pharmaceuticals International operating margin
- Kiniksa Pharmaceuticals International total debt
- Largest health care companies
Further comparisons
Alkermes against its closest peers
Kiniksa Pharmaceuticals International against its closest peers
Learn
Questions and answers
Which is bigger, Alkermes or Kiniksa Pharmaceuticals International?
By market value, Alkermes is the larger: $7.6B against $7.5B for Kiniksa Pharmaceuticals International. By revenue in its latest fiscal year, Alkermes is the larger: $1.5B against $677.6M for Kiniksa Pharmaceuticals International.
Which has the higher operating margin?
Alkermes: 17.2%, against 11.4% for Kiniksa Pharmaceuticals International. Operating margin is operating income as a share of revenue in the latest fiscal year.
Which superinvestors own both Alkermes and Kiniksa Pharmaceuticals International?
In their latest 13F filings, Julian and Felix Baker holds both.
Cite this page
Funkfolio, “Alkermes vs Kiniksa Pharmaceuticals International”, data as of 17 November 2026. https://funkfolio.com/compare/alks-vs-knsa
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.